Nevertheless, the current reviews discuss promising emerging direct genetic detection tests. Tide of Rising Syphilis Becampanel in the United States [3, 7]. As a result, CDC initiated an effort to develop such guidance. The current supplement in marks an important milestone on this path. Currently, all syphilis laboratory testing is a supplement to clinical evaluation and diagnosis, for which clinical guidance exists elsewhere (ie, Becampanel 2015 CDC STD treatment guidelines [8]). This supplement to provides reviews of the laboratory tests that are used to support the clinical diagnosis of syphilis. CDC developed key questions to guide literature and other evidence searches of test performance and optimal specimen types of existing laboratory tests. The key questions were: What are the performance characteristics for each direct detection test for molecular epidemiology? What is the sensitivity and specificity of the nontreponemal and treponemal tests currently approved by the US Food and Drug Administration (FDA) for the diagnosis of syphilis (by stage)? What considerations need to be accounted for when choosing a traditional vs reverse algorithm for diagnosis of syphilis? What is the sensitivity and specificity of the point-of-care treponemal antibody tests currently approved by the FDA for the diagnosis of syphilis? The literature searches were performed by CDC laboratory experts. CDC partnered with the Association of Public Health Laboratories (APHL) to engage subject matter experts (SMEs) who assisted in Becampanel the review of the collected evidence. The syphilis SMEs gathered for an in-person meeting in November 2017 to present and discuss their findings, which were summarized by APHL [9]. The current special supplement is a collection of the presentations that document the experts review methods, analyses, syntheses, and conclusions, which CDC will further use when developing syphilis laboratory guidance. A Direct Detection Assay for infection is urgently needed to identify this infection from clinical specimens. Ideally, this would be a highly sensitive and specific infection presents a challenge due to the low and transient bacterial burden in accessible anatomic sites depending on stage of infection, and the organisms ability to persist in ITGA4 the nervous system. Another substantial obstacle is the previous unavailability of an in vitro culture system to provide ample material for test evaluation; however, Becampanel studies on a sustainable culture method are promising [10]. This would allow full exploration of genetics and suitable, highly expressed genes or antigens. Nevertheless, the current reviews discuss promising emerging direct genetic detection tests. In the US, they are currently only available in a laboratory-developed format using genetic material from primary syphilis lesions. Theel et al present Becampanel a performance summary for nucleic acid amplification tests (NAATs) for lipoprotein tpp47 and DNA polymerase polA gene targets [11]. They document encouraging NAAT performance data with a sensitivity of 75%C95% in primary lesions [11]. This compares well with the reported 73%C100% sensitivity of direct fluorescence antibody and dark field microscopy testing [11]. Further research and development could enhance test performance of NAAT assays, explore utilization of a range of specimen types, and allow adaptation to simple test formats especially at the point of care. However, as summarized by Theel et al [11], the current status of evidence suggests that the tests are still insensitive in blood, with some hopeful signs that they could already be used for neonatal blood or serum as an adjunct method to support diagnosis of congenital disease. These developments highlight the need for these tests and for developers to engage toward approval by the FDA. Subsequent commercialization, hopefully with next-generation improvements and expandable for other syphilis stages, could broaden demand.
